17365-01-4

Basic information

• Product Name: ETIROXATE
• Synonyms: ETIROXATE;CG-63;DL-a-Methyl-thyroxine Ethyl Ester;O-(4-Hydroxy-3,5-diiodo-phenyl)-3,5-diiodo-a-methyl-DL-tyrosine Ethyl Ester;CG-635;DL-α-Methyl-thyroxine Ethyl Ester;O-(4-Hydroxy-3,5-diiodo-phenyl)-3,5-diiodo-α-methyl-DL-tyrosine Ethyl Ester;(±)-2-Amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]-2-methylpropionic acid ethyl ester
• CAS NO: 17365-01-4
• Molecular Formula: C18H17I4NO4
• Molecular Weight: 818.935
• EINECS: 259-593-1
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 17365-01-4.mol

Chemical Properties

• Melting Point: 149-1510C
• Boiling Point: 563.7°C at 760 mmHg
• Flash Point: 294.7°C
• Appearance: /
• Density: 2.321g/cm³
• Vapor Pressure: 2.6E-13mmHg at 25°C
• Refractive Index: 1.721
• Storage Temp.: -20°C Freezer
• Solubility: DMSO, Methanol
• CAS DataBase Reference: ETIROXATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETIROXATE(17365-01-4)
• EPA Substance Registry System: ETIROXATE(17365-01-4)

Safety Data

• Hazardous Substances Data: 17365-01-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETIROXATE is used as an antilipemic agent for the treatment of hyperlipidemia, a condition characterized by elevated levels of lipids in the blood. It helps to lower the risk of cardiovascular diseases by reducing the levels of low-density lipoprotein (LDL) cholesterol and triglycerides, while also increasing the levels of high-density lipoprotein (HDL) cholesterol.
Additionally, ETIROXATE may be used in the development of novel drug delivery systems to improve its efficacy and bioavailability in treating hyperlipidemia. This could involve the use of various organic and metallic nanoparticles as carriers for ETIROXATE delivery, aiming to enhance its therapeutic outcomes and patient compliance.

Originator

Skleronorm,Gruenenthal,W. Germany,1977

Manufacturing Process

7.91 g of α-methyl thyroxine are suspended in 150 cc of ethanol. While heating, the solution is saturated with dry hydrogen chloride. Thereafter, the solvent is distilled off at reduced pressure. The residue is dissolved in a mixture of ethanol and water (1:1). Adding a 5% solution of sodium hydrogen carbonate in water, the ethyl ester of α-methyl thyroxine precipitates; melting point: 156°C to 157°C after recrystallization from ethanol. The yield is 6.05 g, i.e., 74% of the theoretical yield.

Therapeutic Function

Antihyperlipoproteinemic

InChI:InChI=1/C18H17I4NO4/c1-3-26-17(25)18(2,23)8-9-4-13(21)16(14(22)5-9)27-10-6-11(19)15(24)12(20)7-10/h4-7,24H,3,8,23H2,1-2H3

Relevant articles and documents

Pharmaceutical composition comprising d,l-α-methyl-thyroxine ethyl ester and the salts thereof and the control of cholesterol and triglyceride blood level therewith

The invention relates to a new pharmaceutical composition and a method of treating patients.